Core Viewpoint - Wall Street analysts anticipate Labcorp (LH) will report quarterly earnings of $3.49 per share, reflecting a year-over-year increase of 3.3%, with revenues expected to reach $3.26 billion, up 6.7% from the previous year [1] Group 1: Earnings and Revenue Estimates - The consensus EPS estimate has been revised 0.8% lower over the last 30 days, indicating a reevaluation of initial estimates by analysts [1] - Analysts forecast 'Revenues- Diagnostics Laboratories' to reach $2.53 billion, representing a 7.9% increase from the year-ago quarter [2] - 'Revenues- Biopharma Laboratory Services' are projected to be $734.73 million, indicating a 2.2% increase from the previous year [2] Group 2: Operating Income Estimates - 'Adjusted Operating Income- Biopharma Laboratory Services' is expected to be $111.44 million, compared to $109 million from the year-ago period [2] - 'Adjusted Operating Income- Diagnostics Laboratories' is projected to be $409.56 million, up from $386.30 million year-over-year [3] Group 3: Stock Performance - Over the past month, Labcorp shares have declined by 2.9%, while the Zacks S&P 500 composite has increased by 4.5% [3] - Labcorp holds a Zacks Rank 3 (Hold), suggesting its performance will likely align with the overall market in the near term [3]

Core Viewpoint - Wall Street anticipates a year-over-year increase in Labcorp's earnings driven by higher revenues, with the actual results being crucial for stock price movement [1] Earnings Expectations - Labcorp is expected to report quarterly earnings of $3.49 per share, reflecting a year-over-year increase of 3.3% [2] - Revenue projections stand at $3.26 billion, indicating a 6.7% increase from the same quarter last year [2] Estimate Revisions - The consensus EPS estimate has been revised down by 0.76% over the last 30 days, indicating a reassessment by analysts [3] Earnings Surprise Prediction - The Zacks Earnings ESP model shows that Labcorp's Most Accurate Estimate is lower than the consensus estimate, resulting in an Earnings ESP of -0.65%, suggesting bearish sentiment among analysts [4][6] - A positive Earnings ESP is generally a strong predictor of an earnings beat, especially when combined with a favorable Zacks Rank [5] Historical Performance - In the last reported quarter, Labcorp exceeded expectations by posting earnings of $3.94 per share against an expected $3.78, achieving a surprise of 4.23% [7] - Over the past four quarters, Labcorp has consistently beaten consensus EPS estimates [7] Conclusion - Labcorp does not currently appear to be a strong candidate for an earnings beat based on the Earnings ESP and Zacks Rank, but other factors should also be considered for investment decisions [8]

BURLINGTON, N.C., Oct. 10, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on December 13, 2024, to stockholders of record as of the close of business on November 26, 2024. About Labcorp Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, phar ...

Core Insights - Labcorp Holdings Inc. is expanding its testing solutions in strategic growth areas, improving margin performance through the LaunchPad initiative, and forming strategic partnerships to boost growth despite macroeconomic uncertainties and a debt-laden balance sheet [1][2]. Group 1: Financial Performance - Over the past year, Labcorp's stock has increased by 5.9%, outperforming the industry growth of 0.4% but lagging behind the S&P 500's 31.5% gain [2]. - The company has a market capitalization of $18.87 billion and an earnings yield of 6.5%, which is above the industry average of 5.4% [2]. - Labcorp's average earnings surprise over the trailing four quarters is 2.8% [2]. Group 2: Strategic Initiatives - Labcorp is focusing on key growth areas such as oncology, women's health, autoimmune disease, and neurology, with new offerings like the Labcorp Tissue Complete genomic profiling service launched in Geneva and Shanghai [3]. - The company launched the first-trimester screening test for preeclampsia risk, the only test of its kind in the U.S., and received FDA approval for a companion diagnostic for hemophilia B treatment [4]. - The LaunchPad initiative aims for savings of $350 million over three years, with a target of $100 million to $125 million in savings for 2024 [5]. Group 3: Partnerships and Acquisitions - Labcorp completed the acquisition of select BioReference Health assets, enhancing its laboratory services network [6]. - The company also acquired assets from Invitae to improve its specialty testing capabilities and utilize genetic data for clinical trials and treatments [6]. - A strategic collaboration with Naples Comprehensive Healthcare was established to manage inpatient lab operations [7]. Group 4: Debt and Economic Concerns - As of the second quarter of 2024, Labcorp's short-term borrowings and current portion of long-term debt totaled $2.02 billion, with cash and cash equivalents at $265.1 million [8]. - The long-term debt (net of current portion) was reported at $3.05 billion, down from $4.05 billion in the previous quarter [8]. - Macroeconomic factors, including inflation and geopolitical tensions, may impact demand for Labcorp's diagnostic testing and drug development services [7]. Group 5: Earnings Estimates - The Zacks Consensus Estimate for Labcorp's 2024 earnings per share has decreased by 0.4% year over year to $14.61 [9]. - The estimated revenue for 2024 is projected at $12.98 billion, indicating a 0.6% increase from 2023 [9].

BURLINGTON, N.C., Sept. 24, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2024 before the market opens on Thursday, October 24, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webca ...

Labcorp (LH) has announced the expansion of its molecular bioanalytical laboratory in Greenfield, IN. The expanded facility will increase the company's global molecular bioanalytical capacity, enabling the company to help biopharmaceutical customers bring life-saving advanced therapies to patients faster. The latest development is expected to positively boost the company's Central Laboratories business under the Biopharma Laboratory Services ("BLS") segment. Predicting LH Stock Movement Following the News S ...

The American College of Obstetricians and Gynecologists (ACOG) recommends postpartum care be treated as an ongoing process rather than a single doctor's visit. However, estimates suggest that a significant number of women do not attend even one postpartum appointment, in part due to access barriers like lack of health insurance, transportation and childcare. "The postpartum period is a precarious time for women in the United States. Current standards of care provide insufficient support for women who may be ...

Labcorp Holdings Inc. (LH) recently announced the completion of its acquisition of select assets of BioReference Health — a wholly-owned subsidiary of OPKO Health, Inc. (OPK). The transaction is aimed at providing customers with greater access to Labcorp's comprehensive, high-quality laboratory services, scientific expertise and expanded testing capabilities in key regions across the United States. Likely Trend of LH Stock Following the News Following the announcement, shares of Labcorp rose 2.1% to $225.76 ...

Core Viewpoint - Labcorp Holdings Inc. announced the pricing of a $2 billion senior notes offering through its subsidiary, Laboratory Corporation of America Holdings, with three tranches maturing in 2030, 2032, and 2034 [1][3]. Group 1: Offering Details - The offering consists of $650 million of 4.350% Senior Notes due 2030, $500 million of 4.550% Senior Notes due 2032, and $850 million of 4.800% Senior Notes due 2034 [1]. - The notes will bear interest from September 23, 2024, payable semi-annually starting April 1, 2025 [1]. - The 2030 Notes will be issued at 99.931% of par value, the 2032 Notes at 99.608%, and the 2034 Notes at 99.755% [1]. Group 2: Use of Proceeds - Labcorp plans to use the net proceeds to redeem or repay existing indebtedness, including $400 million of 2.30% Senior Notes due December 1, 2024, and $1 billion of 3.60% Senior Notes due February 1, 2025 [3]. - Additionally, $350 million will be used to repay borrowings under its revolving credit facility, with any remaining funds allocated for general corporate purposes [3]. Group 3: Regulatory and Management Information - The offering will be made under an effective shelf registration statement filed with the SEC, including a base prospectus and a prospectus supplement [2]. - The joint book-running managers for the offering include BofA Securities, US Bancorp, and Wells Fargo Securities, among others [4].

Core Insights - Labcorp has completed the acquisition of select assets from BioReference Health, a subsidiary of OPKO Health, aimed at enhancing its laboratory services network and expanding access to clinical services [1][2][3] Group 1: Acquisition Details - The acquisition includes BioReference Health's laboratory testing businesses focused on clinical diagnostics and reproductive and women's health outside of New York and New Jersey, along with certain patient service centers, customer contracts, and operating assets, generating approximately $100 million in annual revenue [2][3] - The total purchase price for the transaction is $237.5 million [2] Group 2: Strategic Implications - Labcorp's Executive Vice President emphasized the commitment to increasing patient access to quality laboratory services and the immediate benefits from Labcorp's scale and expertise [3] - OPKO's CEO stated that the sale of these diagnostic assets is a crucial step towards improving efficiencies and productivity, allowing OPKO to focus on its core clinical diagnostics in New York and New Jersey, as well as higher value testing segments, which generate approximately $400 million in annual revenue [3] Group 3: Financial Advisors - Lazard served as Labcorp's financial advisor, while Piper Sandler & Co. acted as OPKO's financial advisor [4]